Combining CRISPR with conventional pharmaceutical agents can be more effective than using the traditional therapeutic options by themselves. CRISPR has rapidly accelerated drug discovery, identification, and preclinical validation, whether by modifying cells to mimic human pathophysiological conditions, generating screens, or developing transgenic animal models. CRISPR-based immunotherapeutics is being tested for the treatment of cancers, as well as a variety of genetically predisposed conditions including sickle cell anemia. With advances in genome sequencing, it is conceivable to envision a customized treatment plan where DNA-editing drugs are prescribed to a patient to target genome sequencing-revealed mutations. For more information on CRISPR visit our resource center
here.